
Opinion|Videos|March 21, 2025
Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most common logistical challenges you encounter when implementing bispecific therapies?
- What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative Patients
2
Price Transparency With Gaps: Assessing the Completeness of Payer Transparency in Coverage Data
3
Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD
4
T-DXd Delivers Strong Breast Cancer Outcomes Across Groups
5














































